Decitabine 2′-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716

Drugs in R and D

Volumn 4, Issue 6, 2003, Pages 352-358

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IMATINIB; RUBITECAN; AZACITIDINE; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DNA METHYLATION; DRUG APPROVAL; DRUG MARKETING; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DYSURIA; FEVER; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; KIDNEY FAILURE; LEUKEMIA; LEUKOPENIA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SEIZURE; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING; LUNG TUMOR; MALE; PROSTATE TUMOR; REVIEW; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; ANTINEOPLASTIC AGENTS; AZACITIDINE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LEUKEMIA; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS;

EID: 0242690329     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304060-00004     Document Type: Article

References (25)

1. SuperGen Inc. Phase II Clinical Study of Supergen's Dacogen™ And Novartis' Gleevec™ Initiated in Patients with Chronic Myelogenous Leukemia. Media Release: 13 Jun 2003. Available from URL: http://www.supergen.com
2. SuperGen Inc. SuperGen's Decitabine Granted 'Orphan Drug' Status in Europe. Media Release: 28 Feb 2003. Available from URL: http://www.supergen.com
3. SuperGen Inc. SuperGen Completes Patient Enrollment in Investigational Phase III Clinical Study of Decitabine. Media Release: 17 Mar 2003. Available from URL: http://www.supergen.com
4. SuperGen Inc. SuperGen Receives Patent Notice of Allowance for Claims Relating to Dacogen™ (decitabine) as Part of Combination Therapy for Treatment of Multiple Cancer Types. Media Release: 7 Jul 2003. Available from URL: http://www.supergen.com
5. Momparler RL, Bouffard DY, Momparler LF. Pilot phase I-II study on 5-aza-2′-deocycytidine (decitabine) in patients with metastatic lung cancer. Anti-Cancer Drugs 8: 358-368, Apr 1997
6. Petti MC, Mandelli F, Zagonel V, et al. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results. Leukemia 7 (Suppl. 1): 36-41, May 1993
7. Kantarjian H, O'Brien S, Beran M. Results with decitabine, a hypomethylating agent, in the treatment of chronic myelogenous leukemia in accelerated or blastic phases. Blood 88 (Suppl. 1): 199, Part 2, 15 Nov 1996
8. Pinto A, Milan I, Concetta Petti. Decitabine in acute myeloid leukemia and myelodysplastic syndromes. 40th Annual Meeting American Society of Hematology: 6-9, 4 Dec 1998
9. Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11: 1617-1620, Oct 1997
10. Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 11 (Suppl. 1): 24-27, Mar 1997
11. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. Journal of Clinical Oncology 18: 956-962, Mar 2000
12. Lenzi R, Raber MN, Gravel D, et al. Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2′-deoxy-5-azacytidine. International Journal of Oncology 6: 447-450, Feb 1995
13. Vermorken JB, Tumolo S, Roozendaal KJ. 5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix. European Journal of Cancer 27: 216-217, No. 2, 1991
14. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964, 15 Oct 2002
15. SuperGen Inc. Published and Presented Data Suggest SuperGen's Dacogen™ Affords the Opportunity of Multi-Mechanistic Therapeutic Approaches to Cancer Treatment. Media Release: 9 Jun 2003. Available from URL: http://www.supergen.com
16. SuperGen Inc. SuperGen's Dacogen™ Phase II Study Results Published in the Current Issue Of Cancer. Media Release: 30 Jul 2003. Available from URL: http://www.supergen.com
17. Richel DJ, Colly LP, Kluin-Nelemans JC. The antileukaemic activity of 5-aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. British Journal of Cancer 64: 144-148, Jul 1991
18. Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. Leukemia 7 (Suppl. 1): 49-50, May 1993
19. Sacchi S, Kantarjian HM. Decitabine is effective for the treatment of chronic myelogenous leukemia in non-lymphoid blastic phase. 40th Annual Meeting American Society of Hematology: 12-14, 4 Dec 1998
20. Giralt S, Cohen A, Davis M. Phase I/II study of decitabine with allogeneic peripheral blood stem cell transplantation for treatment of relapse after allogeneic progenitor cell transplantation. 40th Annual Meeting American Society of Hematology: 15-16, 4 Dec 1998
21. Ravandi F, Kantarjian H, Cohen A, et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplantation 27: 1221-1225, No. 12, Jun 2001
22. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86: 2632-2641, 15 Dec 1999
23. SuperGen Inc. Supergen's Decitabine Active as Part of Combination Preparative Regimen for Allergenic Blood and Bone Marrow Transplants. Media Release: 31 Mar 2003. Available from URL: http://www.supergen.com
24. SuperGen Inc. Studies Suggest SuperGen's Decitabine is Effective in Elderly Patients with High-Risk Myelodysplastic Syndrome (MDS). Media Release: 6 Dec 2002. Available from URL: http://www.supergen.com
25. Koshy M, Dorn L, Bressler L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96: 2379-2384, 1 Oct 2000